Swine Vaccines Market: Current Analysis and Forecast (2022-2028)

Swine vaccines are used to prevent and control a wide range of diseases that affect pigs. These diseases can cause significant economic losses for swine producers, and in some cases, they can also pose a public health risk. Swine vaccines help to prevent and control diseases, reduce the need for antibiotics, and improve the overall health and welfare of pigs. The swine vaccine market is expected to continue to grow due to increasing demand for pork and swine products, advances in vaccine technology, and the emergence of new and complex swine diseases. Vaccination is a key tool in protecting swine health and ensuring food safety, and it will continue to play an important role in the swine industry in the years to come.

The swine vaccines market is expected to grow at a steady rate of around 5% owing to due to increasing demand for pork and other swine products, as well as the growing awareness of the importance of vaccination in animal health. The market is also driven by advances in vaccine technology, increasing government initiatives for animal health, and the emergence of new and complex swine diseases.

Based on product type, the market is segmented into attenuated live vaccines, inactivated vaccines, subunit vaccines, DNA vaccines, and recombinant vaccines. The inactivated vaccines category is to witness higher CAGR during the forecast period. This is mainly due to the inactivated vaccines are considered to be very safe, as they cannot cause disease in the person being vaccinated, these vaccines are often more stable than live vaccines, more effective at stimulating an immune response, and ability to rapidly respond to emerging diseases are factors contributing to the growing popularity this segment.

On the basis of type, the market is categorized into swine influenza, classical swine fever, porcine parvovirus, porcine circovirus type 2, and m.hyo. Among these, the porcine parvovirus held a significant share in the market in 2021. This is mainly due to the high prevalence of porcine parvovirus in pig herds worldwide, there is a high demand for vaccines to control and prevent its spread. In addition, several major animal health companies manufacture and distribute porcine parvovirus vaccines, which also contributes to its dominance in the market.

For a better understanding of the market adoption of the swine vaccines industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the increasing demand for pork meat, rising prevalence of swine diseases, and government initiatives for livestock disease control. The Asia region, which includes countries such as China, India, Japan, South Korea, and Thailand, is one of the largest producers of pork in the world.

China is the largest market for swine vaccines in the Asia region, accounting for a significant share of the global market. The country is the world's largest pork producer, and the increasing demand for pork meat, along with the growing prevalence of swine diseases such as African swine fever, has led to a surge in demand for swine vaccines. For instance, in April 2022, Scientists with the United States Department of Agriculture's Agricultural Research Service (ARS) announced that a vaccine candidate for African Swine Fever (ASF) passed an important safety test required for regulatory approval, moving the vaccine one step closer to commercial availability.

Some of the major players operating in the market include: Merck & Co., Inc.; Ceva; Zoetis; Boehringer Ingelheim International GmbH; Elanco; Indian Immunologicals Ltd.; Biogenesis Bago; Phibro Animal Health Corporation; KM Biologics; and HIPRA, S.A.